Determination of quality indicators of a combined nootropic drug
- Authors: Abdunazarov A.I.1, Tashpulatova A.D.2
-
Affiliations:
- «Temur Med Farm» LLC
- Tashkent Pharmaceutical Institute
- Issue: Vol 73, No 2 (2024)
- Pages: 40-45
- Section: Pharmaceutical chemistry and pharmacognosy
- URL: https://bakhtiniada.ru/0367-3014/article/view/254097
- DOI: https://doi.org/10.29296/25419218-2024-02-06
- ID: 254097
Cite item
Open Access
Access granted
Subscription Access
Abstract
Introduction. The state drug policy of the Republic of Uzbekistan is aimed at the release of new affordable import-substituting drugs of domestic production, which are not inferior in activity to foreign analogues. Taking this into account, and also taking into account the high cost of imported nootropic drugs, the pharmaceutical production of LLC «Тemur med farm», Syrdarya region, Uzbekistan has developed the composition, technology and production of the combined drug "Nootrotem". "Nootrotem" is a combined preparation of piracetam and methylethylhydroxypyridine succinate in an injectable dosage form. Based on preclinical pharmacological studies, the pronounced nootropic and metabolic effects of the studied drug have been proven.
Objective: The purpose of these studies is to develop quality assessment methods and establish quality indicators of the combined drug "Nootrotem" solution for infusions.
Material and methods. 5 series of laboratory samples of the drug "Nootrotem" solution for infusions obtained at the pharmaceutical production "Temur med farm", Uzbekistan, were used as research objects.
Results. The determination of the quality indicators of the studied drug was carried out in accordance with the modern requirements of the National pharmacopoeia of the Republic of Uzbekistan and the European pharmacopoeia, as well as in accordance with the general technical regulations on the safety of medicines.
Conclusion. As a result of the conducted research, the main quality indicators of the drug "Nootrotem" solution for infusions were established according to the following indicators: description, authenticity, transparency, chromaticity, pH, package filling volume, mechanical inclusions, impurities, residual sulfur dioxide, osmolality. The limits of their rationing have been established in accordance with the State Budget of the Republic of Uzbekistan.
Full Text
##article.viewOnOriginalSite##About the authors
Azamat I. Abdunazarov
«Temur Med Farm» LLC
Author for correspondence.
Email: azamat.abdunazarov@gmail.com
ORCID iD: 0009-0008-8471-5519
Quality Director; 2nd year candidate in the direction 15.00.02 “Pharmaceutical chemistry and pharmacognosy”
Uzbekistan, Osuda khayet str., 44, Syrdarya district, Syrdarya regionAzizakhon D. Tashpulatova
Tashkent Pharmaceutical Institute
Email: aiza2505@mail.ru
ORCID iD: 0009-0000-5428-9039
Doctor of Pharmaceutical Sciences, Associate Professor, Professor of the Department of Pharmaceutical Chemistry
Russian Federation, Aybek str., 45, Tashkent, 100015References
- Лавренчук Р.А., Сакаева И.В., Саканян Е.И. Контроль качества лекарственных форм для парентерального применения: современное состояние. Ведомости научного центра экспертизы средств медицинского применения. 2012; 2: 42. [Lavrenchuk R.A., Sakaeva I.V., Sakanyan E.I. Quality control of dosage forms for parenteral use: current state. Bulletin of the scientific center for the examination of medical products. 2012; 2: 42 (in Russian)]
- Моисеева Е.В. Обеспечение качества инфузионных растворов по показателю «Механические включения». Автореферат диссертации на соискание степени кандидата фармацевтических наук 15:00:01, РФ, 2004. [Moiseeva E.V. Ensuring the quality of infusion solutions according to the indicator "Mechanical inclusions". Abstract of the dissertation for the degree of Candidate of Pharmaceutical Sciences 15:00:01, Russian Federation, 2004 (in Russian)]
- Краснов Е.А., Кадырова Т.В. Стандартизация лекарственных средств. Учебное пособие. Томск, 2005; 11–2. [Krasnov E.A., Kadyrova T.V. Standardization of medicines. Textbook. Tomsk, 2005; 11–2 (in Russian)]
- Янишевский С.Н. и др. Современные стратегии защиты при гипоксически-ишемическом повреждении головного мозга. Журнал неврологии и психиатрии. 2017; 12 (2): 78–86. [Yanishevsky S.N. et al. Modern protection strategies for hypoxic-ischemic brain damage. J. of Neurology and Psychiatry. 2017; 12 (2): 78–86. https://doi.org/10.17116/jnevro201711712278-86 (in Russian)]
- Касимов Э.Р., Абдуназаров А.И. Оценка специфической и острой токсичности нового отечественного ноотропного препарата. Вестник Ташкентской медицинской академии. 2020; 6: 79–83. [Kasimov E.R., Abdunazarov A.I. Evaluation of specific and acute toxicity of new domestic nootropic preparation. Bulletin of the Tashkent Medical Academy. 2020; 6: 79–83 (in Russian)]
- Государственная фармакопея Республики Узбекистан, 1 издание, том 1, 2021 [State Pharmacopoeia of the Republic of Uzbekistan, 1st edition, volume 1, 2021 (in Russian)]
- Европейская фармакопея 8.0, Том 2. [European Pharmacopoeia 8.0, Volume 2 (in Russian)]
- Общий технический регламент о безопасности лекарственных средств (Приложение к Постановлению КМ РУз от 27.10.2016г. №365). [General technical Regulations on the safety of medicines (Appendix to the Resolution of the Cabinet of Ministers of the Republic of Uzbekistan dated 10/27/2016 No. 365) (in Russian)]
Supplementary files
